BlackBio’s target is to lead the research and development of new tools in the field of personalized medicine, medical diagnostics and pharmacogenomics.

The company therefore uses and adapts a wide spectrum of technologies that include the most innovative sequencing platforms, protein arrays and other molecular analysis solutions in the areas of metabolic disorders , oncology, cardiovascular diseases, microbiology, pharmacogenetics and wellness.

BlackBio's patented technologies provide this pioneering project with the required means to develop and launch high quality products and technical solutions. BlackBio tests and services are characterized by their ease of use, reduced and fast workflow, flexibility and cost competitiveness, offering reliability and simplicity to partners and customers from the healthcare sector, as well as for pharma and biotech companies.

BlackBio therefore makes an important step towards converting the presently complex and high cost field of Personalized Medicine into an affordable reality for public & private healthcare systems, as well as for pharma and diagnostic companies.

The company is backed by Biotools B&M Labs, S.A., a leading European Biotech company with more than 14 years of experience on a global scale, with facilities in Spain and Brazil.